Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Price:
0.159 USD
1.02%
Market Closed
Updated:
Apr 24, 2024
Sonoma Pharmaceuticals Inc
Net Income (Common)
Last
Value
3-Years CAGR
5-Years CAGR
|
Sonoma Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Net Income (Common)
-$5.1m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$40.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$2.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$365m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-22%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Sonoma Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-5.1m
USD
-5.1m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Net Income (Common) amounts to -5.1m USD.
What is Sonoma Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
2%
2%
Over the last year, the Net Income (Common) growth was 25%. The average annual Net Income (Common) growth rates for Sonoma Pharmaceuticals Inc have been -36% over the past three years , 18% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
